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Background: Women have less favorable outcomes compared with men after
ST-segment elevation myocardial infarction (STEMI) for as yet unclear reasons.
Methods: The INFUSE-AMI trial randomized patients with STEMI due to proximal or
mid LAD occlusion to intracoronary bolus abciximab (ClearWay RX catheter) vs. no
abciximab, and to thrombus aspiration (Export) vs. no aspiration. We compared infarct
size as % of LV mass assessed by magnetic resonance imaging at 30-days, angiographic
and electrocardiographic markers of reperfusion and 30-day major adverse cardiovascular
events (MACE) according to gender.
Results: Among 452 patients, women (118, 26.1%) were older, and had a higher
prevalence of hypertension, hyperlipidemia and diabetes. They were more likely to
undergo PCI3 hours after the onset of symptoms (47.5% vs. 25.1 %, p0.0001). There
were no significant differences among men and women in post-procedure TIMI 3 flow,
89.8% vs. 91.9%; myocardial blush grade 3, 67.8% vs. 70.0%; complete ST resolution,
56.9% vs. 50.3% and infarct size, median [IQR] % total LV mass, 17.0% [6.8-24.8] vs.
17.3% [9.5-23.5]. Unadjusted MACE at 30 days was higher in women (Fig) but after
adjustment for confounders, female gender was not significantly associated with increased
MACE (HR 1.59, 95% CI 0.75-3.33, p0.23).
Conclusions: In INFUSE-AMI, women compared to men with anterior MI had longer
times from presentation to PCI and higher unadjusted MACE rates which were
attributable to baseline differences in risk factors and delayed treatment times, but not to
different infarct size.
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Background: Earlier data suggested a higher risk of procedure related complica-
tions and worse clinical outcomes after percutaneous coronary intervention (PCI)
in female as compared to male patients. However, these results still need
confirmation due to the lower representation of women in clinical trials and
improved devices and techniques. We aim to investigate procedure characteristics
and clinical outcomes after PCI using drug-eluting stent with biodegradable
polymer in female versus male patients in a real world setting.
Methods: Among 3,067 consecutive patients enrolled in the NOBORI 2 study, and
treated with Nobori drug eluting stent (DES), 676 were female. Primary endpoint
was target lesion failure (TLF) defined as a composite of cardiac death, target
vessel related myocardial infarction (MI) and target lesion revascularization
(TLR) at 1 year post-procedure. Adjudication and data analysis were performed
by an independent clinical event committee and corelab, respectively.
Results: Female patients were significantly older compared to male (6810 vs
6311y), had a higher incidence of hypertension (76.8% vs 66.9%) and diabetes
(37.5% vs 27.2%) and showed a higher Charlson Comorbidity Index (3.61.7 vs
3.11.8; p0.001). In contrast, female patients displayed a lower frequency of
previous MI (29.4% vs 34.2%; p0.02), PCI/CABG (31.9% vs 43.6%; p0.001)
and smoking. A lower number of diseased vessels and lesions were detected and
treated in female patients. The lesions were less often located in the LCx (19.4%
vs 27.8%; p0.001) and at bifurcation (16.5% vs 21.5%; p0.001). At 3-year
follow-up, the TLF rate was low in both groups (6.2% female vs 6.6% male
group), with similar cardiac death (2.4% vs 2.2), TV-MI (2.5% vs 2.3%), TLR
(3.6% vs 3.4%) and TVR (5.2% vs 5.4%) rates. Stent thombosis up to three years
were low and similar in both subgroups (1.3% vs 0.8%).
Conclusions: Despite differences in the demographics and risk factors between female
and male patient’s population, no long-term difference in clinical outcome was observed
between subgroups and treatment with Nobori, DES with biodegradable polymer was
proven to be equally safe and efficient in both patient groups.
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Background: Previously we reported increased MACE in lower socioeconomic status
(SES), public health system (PHS) patients (pts) undergoing PCI. We report expanded /
extended analyses, focused on distribution and impact of cardiac risk factors.
Methods: 2,000 pts undergoing PCI over 6 years at Cook County Hospital,Chicago,IL
were studied. Complete data and follow-up within the PHS was mandatory for inclusion.
SES was assessed via geographic household income determination and divided into
above/below median income. Pts were followed for occurrence of MACE (death,
myocardial infarction and urgent revascularization). Descriptive statistics and survival
analyses were performed.
Results: 1,985 pts (age 57.2 10.2, 31.9% female, 36.4% diabetes, median income
$38,044) underwent PCI for STEMI(19.3%),NSTEMI(26.9%),unstable
angina(24.0%),stable angina(20.3%)or LV dysfunction(3.3%). Follow-up was obtained in
97.3% (mean 2.5  1.9 yrs). There was far greater (9.2% absolute/30% relative) MACE
and mortality in lower-SES pts, with the gap increasing over time (Fig 1.) Several
important risk factors were more prevalent in lower-SES pts: female gender, smoking,
cerebrovascular disease, unstable presentation. The majority (71%) of lower-SES pts were
black whereas the higher-SES group was racially diverse.
Conclusions: Lower socioeconomic status portends remarkably poor post-PCI outcomes
even when access to care is uniform within a PHS hospital. The impact of unevenly
distributed risk factors is noted and currently being studied in a multivariate model. Racial
disparities pose another concerning, if poorly understood, variable.
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Background: Women have a lower risk for coronary artery disease (CAD) and present
at an older age with multiple comorbidities. Young women who present with CAD, albeit
uncommon, likely reflect accelerated progression of atherosclerosis. It is unclear whether
presentation of CAD in women younger than 55 translates into higher rates of target lesion
revascularization (TLR) and target vessel revascularization (TVR) post percutaneous
coronary intervention (PCI). We compared rates of TLR and TVR at 1 year post PCI in
women younger and older than 55.
Methods: 2219 women who underwent PCI at Washington Hospital center for an acute
coronary syndrome were divided by age into four groups (less than 35: 14 patients, 35-45:
83 patients, 45-55: 295 patients, and older than 55: 1827 patients). TLR and TVR were
recorded at 1 year (2030 and 2044 patients respectively).
Results: There were no significant difference in the use of stents, use of drug eluting
stents (DES), stent number, length or diameter in the different age groups. There were no
differences in post PCI care with anti-platelet and statin therapy. Rates of TLR and TVR
were significantly different among the various age groups with higher rates in younger
groups:
Conclusions: Despite comparable rates of stent use, including DES, and comparable post
PCI medical management, women in the younger age groups had higher rates of TLR and
TVR at 1 year post PCI. Coronary artery disease in younger women likely reflects a more
accelerated progression of the disease warranting close follow up.
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Background: Drug-eluting stents (DES) for the treatment of unprotected left main
coronary artery (ULMCA) disease have been shown to be safe and effective. The aim was
to assess clinical outcomes according to sex in this subset of patients.
Methods: All consecutive patients from our single-center prospective registry treated for
ULMCA stenosis with both first- and new-generation DES from January 2005-June 2010
were analyzed. The study objectives were all-cause mortality, major adverse cardiac
events (MACE), target vessel revascularization (TVR) and target lesion revascularization
(TLR) at 2-years clinical follow-up.
Results: A total of 173 patients were included in the analysis. Notably, only 17.9% were
females. No differences were observed between genders in baseline clinical characteris-
tics. Regarding lesion characteristics, males were more likely to have distal ULMCA
lesions affecting the bifurcation (83.8% vs. 61.3%; p0.005) and undergo a 2-stent
strategy (50.4% vs. 25.8%; p0.013). In addition, males were significantly more likely to
undergo paclitaxel-eluting stent implantation (34.5% vs. 9.7%; p0.006). At 2-years
clinical follow-up, there was a trend for increased all-cause mortality in females (12.9%
vs. 4.2% vs. p0.061). Conversely, there were no significant differences in TLR between
females and males respectively (6.5% vs. 6.3%; p0.981), TVR (22.6% vs. 14.1%;
p0.238), MI (3.2% vs. 1.4%; 0.483), MACE (29.0% vs. 16.9%; p0.119). Moreover,
there were 4 definite/probable stent thrombosis, all in first-generation DES, however this
was not affected by the sex of the patient (3.2% vs. 2.1%; p0.709).
Conclusions: Treatment with DES for ULMCA appears safe and effective regardless of
sex. Despite more distal bifurcation lesions amongst males, there was a trend for a higher
all-cause mortality amongst females which clearly needs to be assessed with larger patient
numbers.
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Background: Right Ventricular Failure (RVF) is a clinical problem associated with a
high mortality that occurs in a variety of settings including post-cardiotomy cardiogenic
shock, cardiac transplant, right ventricular infarction, pulmonary embolism and after left
ventricular assist device (LVAD) implantation. Temporary mechanical right ventricular
support could be a reasonable alternative treatment option in these patients. We report
here the initial first clinical evaluation of a novel minimally invasive percutaneous right
ventricular assist device.
Methods: Impella RP is a new, minimally invasive, 3D catheter-based percutaneous
microaxial pump that is designed for short-term right ventricular support. The device requires
single vascular access through a sheath in the femoral vein. The device (22 Fr pump mounted
on an 11 Fr catheter) is positioned under fluoroscopic guidance using a 0.025wire. It aspirates
blood from the inferior vena cava and expels it into the pulmonary artery at the maximum rate
of up to 4.4 liters per minute. The device requires low anticoagulation regimen.
Results: A First in Man pre-market clinical feasibility evaluation has been initiated at several
sites in Canada and Europe in patients experiencing right ventricular failure in different clinical
settings.Indications for use at the time of this submission included RVF post heart transplant
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